Stockreport

Verastem Oncology Announces Preliminary Data from Investigator-initiated Study Highlighting Clinical Activity of RAF/MEK and FAK Combination in KRAS Mutant Tumors Presented at the American...

Verastem, Inc.  (VSTM) 
Last verastem, inc. earnings: 10/29 04:17 pm Check Earnings Report
US:NASDAQ Investor Relations: verastem.com
PDF Combination of VS-6766 and Defactinib Demonstrates 67% (4/6 Patients) Overall Response Rate in KRAS Mutant Low-Grade Serous Ovarian Cancer in Phase 1 TrialSubsequent Com [Read more]